EP PerMed
European Partnership
for **Personalised Medicine**

Joint Transnational Call for Proposals (2025)

Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)

(EP PerMed Grant 101137129)

Announcement

For further information, please visit our website: www.eppermed.eu

or contact the EP PerMed Joint Call Secretariat (JCS)

The German Aerospace Center e.V. – Project Management Agency, (DLR-PT)

Heinrich-Konen-Straße 1, 53227 Bonn, GERMANY

Alexandra Becker, Katja Kuhlmann

Phone: +49 (0) 228 3821 2211

PerMed@dlr.de

Co-funded by the European Union

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101137129.

Announcement for the Joint Transnational Call (JTC) 2025

The **European Partnership for Personalised Medicine, EP PerMed,** supported by the European Union under Horizon Europe, Grant Agreement N° 101137129, has launched its second joint transnational call (JTC2025) for proposals on "Pharmacogenomic strategies for personalised medicine approaches (PGxPM2025)". In total, 35 funding organisations participate in this call with an available budget of over 36.5 Mio. € (approx.).

EP PerMed funding organisations, listed below, have agreed to jointly fund multinational innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe in this field.

The call will be implemented in two stages, i.e. a pre- and a full-proposal phase.

Expected timeline of the call

16 December, 2024	Publication of the call
09 January 2025	JTC2025 information day
18 February, 2025 (14:00, CET)	Deadline for pre-proposal submission
Expected around 15 May, 2025	Communication of the results of the pre-proposal assessment and invitation to the full-proposal stage
17 June, 2025 (14:00, CEST)	Deadline for full-proposal submission
Mid/end of August 2025	Rebuttal stage
Expected for October 2025	Communication of the funding decisions to the applicants
End of 2025, beginning of 2026	Expected project start (according to regional/national funding regulations)

Electronic submission website

Electronic proposal submission is mandatory on **PT-Outline**. Research project consortia who intend to submit a transnational proposal should register as soon as possible, by clicking on **"Sign up"** and follow further instructions.

Contact persons for the Joint Call Secretariat (JCS)

The **EP PerMed JCS** is hosted by the **German Aerospace Center e.V. – Project Management Agency, (DLR-PT)**:

Alexandra Becker and Katja Kuhlmann
Heinrich-Konen-Straße 1, 53227 Bonn, Germany
Phone: +49 (0) 228 3821 2211
Email: **permed@dlr.de**

Aims of the Call

The overall objectives of the JTC2025 will be to

- Support research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address one or more of the following aspects:
    - **identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.**
    - **validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.**
    - **use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).**
- Encourage and enable interdisciplinary collaborations, i.e. multi-actor research by engaging a range of other relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to support the implementation of the research outcomes into clinical practice.
- Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations.
- Establish participatory research, i.e. active representation of patients or citizens as part of research projects.

Projects are encouraged to **combine the following aspects** in their research:

1. Omics data such as epigenomics, transcriptomics, proteomics and metabolomics data in addition to genomics data in relation to treatment outcomes. A key goal is to assess the importance of one or more -omics approaches (multi-modal approaches) in optimising treatment outcomes.
2. Information regarding patient medication (prescription and non-prescription), dose or compliance.
3. Information (including clinical and environmental factors) regarding medication efficacy, adverse effects and patient reported outcomes (PRO).

Participatory research should be established in that active representation of patients or citizens is part of research projects. EP PerMed is supporting this approach by providing dedicated funding to organisations representing patients or citizens to participate as partners in proposals submitted to this call. Those organisations could support in designing the research, ensuring that research questions are relevant from the patients' and citizens' point of view. They might also support in collecting data for PROs and adverse effects.

Projects funded under this call are furthermore required to **include a dedicated work package focussing on the question of implementation of the research outcomes** into clinical practice with a focus on e.g. patient outcome, costs, reimbursement, education, ELSA (ethical, legal and societal aspect) or feasible use at the point of care.

Research projects in all disease areas are welcome. Research on polygenic drug response phenotypes is encouraged.
Exclusion: Projects focussing only on drug-drug-interaction are out of scope. Projects focusing on the clinical development of new drugs are out scope.

Please refer to the Call Text of the JTC2025 for further information and definitions.

General (Eligibility) Conditions for Application

Joint research proposals may be submitted by applicants belonging to an entity according to the following categories (subject to regional/national funding regulations; see "Guidelines for Applicants"):

A. Academia (research teams working in universities, other higher education institutions) **or research institutes;**

B. Clinical/public health sector (research teams working in hospitals/public health and/or other healthcare settings and health organisations). Participation of clinicians (e.g. medical doctors, nurses), pharmacists and general practitioners in the research teams is encouraged;

C. **Private for-profit (industry) partners, e.g. SME**[1] (small and medium-sized enterprises) **and private non-profit partners**, e.g. foundations, associations or non-governmental organisations.

Consortia submitting applications to this call are strongly encouraged to include partners from different categories (A, B and C) in line with the crosscutting/multidisciplinary nature of the call.

Only transnational projects will be funded. **Each consortium must involve at least three partners from three different EU Member States or Associated Countries whose funding organisations participate in the call. Each of these partners must be eligible and request funding from the respective funding organisation.** All three legal entities must be independent of each other**. The project coordinator must be eligible to be funded** by his/her regional/national participating funding organisation. The project coordinator (i.e. principal investigator and organisation) cannot be changed between the first and second stage.

Max. 2 project partners per consortium can request funding from the same funding organisation. For some funding organisations, the maximum number of eligible partners who can be funded in one project is limited to one (see also "Guidelines for Applicants" for individual funding rules).

No more than one partner with their own funding is allowed in the consortia with at least three partners eligible for funding (more indications in the Call Text: "B. Funding recipients", section 7).

Pre-proposal stage: Maximum number of partners is 6 (no more than 2 partners from the same country including partners on own funding); Maximum number of partners can be 7 if the consortium includes a 3rd partner of the same country (condition: funding requested from at least 2 different funders of the respective country; applies to only one country per consortium; including partners on own funding).

Widening concept: Consortia are allowed to include in the full-proposal phase an additional project partner that is eligible to receive funding from a funding organisation that is underrepresented in the second stage of the call and that agrees to participate in the widening option (a list of underrepresented regions/countries will be provided to coordinators invited to submit full-proposals).

Exception: To facilitate the integration of organisations representing patients or citizens in consortia, they can be added as additional partners at the pre-proposal stage or full-proposal stage. Organisations representing patients or citizens can be added as additional partner(s) either on own funds or by applying for funding, if eligible, from EP PerMed (see page 10) or the respective funding organisations. The consortia must follow all of the above-mentioned rules regarding the consortia composition without counting the patient/citizen representing organisations, except for the following rule: **within one consortium, no more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding organisations, the maximum number of eligible partners who can be funded in one project is one.

[1] https://ec.europa.eu/growth/smes/business-friendly-environment/sme-definition_en

Each project partner has to be represented by **one principal investigator**. Within a joint proposal, each project partner's principal investigator will be the contact person for the JCS and the relevant regional/national funding organisation. Each consortium must nominate one **project coordinator** among the project's principal investigators. The nomination of a project co-coordinator is not allowed.

If a **partner** is found to be ineligible by one of the funding organisations after the formal check, the entire proposal may be rejected without further review. For a definition of eligible partners, see "Guidelines for Applicants", the regional/national regulations, and contact the concerned regional/national funding organisation.

A maximum project duration of 3 years may be applied for.

Number of partners in the proposal*	**Pre-proposal**					**Full-proposal** (only by inclusion of one underrepresented region/country)
	3	**4**	**5**	**6**	**7**	**+1**
Maximum number of partners with own funding**	0	1	1	1	1	1
Maximum number of partners per country***	1	2	2	2	3	3 (for consortia with 8 partners)

* at least three partners being eligible and request funding from three different EU Member States or Associated Countries whose funding organisations participate in the call. Patient/citizen representing organisations are not included in this calculation.

** patient/citizen representing organisations are not included in this calculation and can be added as partners participating with own funding at the pre- and full-proposal stage.

*** patient/citizen representing organisations are not included in this calculation and can be added as additional partners in the pre-proposal or full-proposal stage. They can participate either on own funds or apply for funding, if eligible, from the regional/national funding organisation or EP PerMed. Please note: **within one consortium, not more than 2 partners can request funding from the same funding organisation, including patient/citizen organisations.** For some funding agencies, the maximum number of eligible partners who can be funded in one project is one.

All eligibility criteria and submission requirements are detailed in the following two call documents: "Call text" and the "Guidelines for Applicants".

Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EP PerMed funding organisation respective of the region/country from which applicants applies. The applications are therefore subject to eligibility criteria and regulations of individual funding organisations. Applicants are strongly advised to contact their regional/ national representatives of the participating relevant funding organisation as soon as possible in order to confirm their eligibility (see also below "*Contact details of participating members*").

EP PerMed Partnering Tool

The new partnering tool **https://www.b2match.com/e/eppermed-partnering** will open soon.

Contact details of participating members

The following countries (24) are participating in the call: Austria, Belgium, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, South Africa, Spain, Sweden and Turkiye (contact list is provided below and in Annex 1 of the Call Text as well as the "Guidelines for Applicants" document).

Besides national funders, the following regions are participating (10): Flanders (Belgium), Wallonia-Brussels Federation (Belgium), Saxony (Germany), Lombardy (Italy), Tuscany (Italy), Azores (Portugal), Centro Region (Portugal), Andalusia (Spain), Catalonia (Spain) and Navarre (Spain).

Contact list

Name of participating organisation	*Country/Region*	*Regional/National contact*
Austrian Science Fund, (FWF)	Austria	Hannes Zwickl hannes.zwickl@fwf.ac.at Tel.: +43 676 83487 8219 Heike Höller heike.hoeller@fwf.ac.at Tel: +43 676 83487 8220
The Research Foundation – Flanders, (FWO)	Belgium (Flanders)	Toon Monbaliu (FO) Kristien Peeters (SBO) europe@fwo.be Tel.: +32 (0)2 550 15 70 Tel.: +32 (0)2 550 15 95
Fund for Scientific Research – FNRS, (F.R.S.-FNRS)	Belgium (Wallonia-Brussels Federation)	Maxime Bonsir international@frs-fnrs.be Tel.: +32 2504 9236
The Ministry of Health of the Czech Republic / Czech Health Research Council, (MZCR/AZVCR)	Czech Republic	Monika Kocmanova Monika.kocmanova@azvcr.cz Tel.: +420 606 273 871
Innovation Fund Denmark, (IFD)	Denmark	Katrine Boeriis katrine.boeriis@innofond.dk internationale@innofond.dk Tel.: +45 61 90 50 06
Estonian Ministry of Social Affairs, (MoSAE)	Estonia	Mari Teesalu Mari.teesalu@sm.ee Tel.: +372 5916 2047
Estonian Research Council, (ETAG)	Estonia	Margit Suuroja Margit.Suuroja@etag.ee Tel.: +372 731 7360 Argo Soon Argo.Soon@etag.ee Tel.: +372 515 3424
Business Finland, (BFRK)	Finland	Norma Jäppinen norma.jappinen@businessfinland.fi Matti Hiltunen matti.hiltunen@businessfinland.fi Tel.: +358 50 5577 012 Tel.: +358 50 5577 652
Agence Nationale de la Recherche, (ANR)	France	Monika Frenzel Mylène Vaillancourt EPPerMed@agencerecherche.fr Tel: (+33) (0) 1 73 54 83 32
Federal Ministry of Education and Research, (BMBF) ***German Aerospace Center e.V. – Project Management Agency, (DLR)***	Germany	Ute Preuss Jacqueline Kalb permed@dlr.de Tel.: +49 228 3821-2211

Name of participating organisation	*Country/Region*	*Regional/National contact*
Federal Ministry of Health, (BMG) ***German Aerospace Center e.V. – Project Management Agency, (DLR)***	Germany	Fabian Gondorf permed@dlr.de Tel.: +49 228 3821-2211
Saxon State Ministry for Science, Culture and Tourism, (SMWK)	Germany (Saxony)	Gabriele Süptitz gabriele.sueptitz@smwk.sachsen.de Tel.: +49 351 564-64210 Caroline Karapanos caroline.karapanos@smwk.sachsen.de Tel.: +49 351 564-64210
General Secretariat for Research and Innovation, (GSRI)	Greece	Foteini Karagkouni f.karagkouni@gsrt.gr Tel.: +30 213 1300132
National Research, Development and Innovation Office, (NKFIH)	Hungary	Zsuzsanna Kürti nemzetkozi@nkfih.gov.hu zsuzsanna.kurti@nkfih.gov.hu Tel.: +36 70 375 0036
The Icelandic Centre for Research, (RANNIS)	Iceland	Helga Snævarr Kristjánsdóttir Helga.s.kristjansdottir@rannis.is
Taighde Éireann-Research Ireland, (TE-RI)	Ireland	Emma McGrath Emma.mcgrath@researchireland.ie eu-Cofund@sfi.ie Tel.: +353 86 1991351
Chief Scientist Office, Ministry of Health, (CSO-MOH)	Israel	Liron Even-Faitelson Liron.ef@moh.gov.il Tel.: +972-2-5082168
Italian Ministry of Health, (IT-MoH)	Italy	Maria Josefina Ruiz Alvarez mj.ruizalvarez-esterno@sanita.it Tel.: (+39) 06-4990 6836 Chiara Ciccarelli c.ciccarelli@sanita.it Tel.: (+39) 06-5994 3919
Fondazione Regionale per la Ricerca Biomedica, (FRRB)	Italy (Lombardy)	Giulia Maria Rossignolo bandi@frrb.it Tel.: +39 0267650159
Tuscany Region, (RT)	Italy (Tuscany)	Donatella Tanini Teresa Vieri eppermed@regione.toscana.it Tel.: +39 055 4383256 Tel.: +39 055 4383289
Latvian Council of Science, (LZP)	Latvia	Uldis Berkis Uldis.Berkis@lzp.gov.lv Tel.: +37129472349
Research Council of Lithuania, (LMT)	Lithuania	Živilė Ruželė zivile.ruzele@lmt.lt Tel.: (+370) 676 14383

Name of participating organisation	*Country/Region*	*Regional/National contact*
Luxembourg National Research Fund, (FNR)	Luxembourg	Gideon Gießelmann gideon.giesselmann@fnr.lu Tel.: +352 691 362 805
The Research Council of Norway, (RCN)	Norway	Katrine Rolid karo@rcn.no Tel.: +47 415 48 328
National Centre for Research and Development, (NCBR)	Poland	Anna Stępień anna.stepien@ncbr.gov.pl Tel.: +48 22 39 07 210
Fundação para a Ciência e a Tecnologia, (FCT)	Portugal	Rita Cavaleiro Pedro Ferreira EPPerMed@fct.pt Tel.: +351 213 911 541 Tel.: +351 213 924 445
Vice-Presidency of Azores Regional Government, (VP-GRA)	Portugal (Azores)	Maria Vale Tel.: +351 296 308 922 Maria.LA.Vale@azores.gov.pt
Comissão de Coordenação e Desenvolvimento Regional do Centro, (CCDRC)	Portugal (Centro Region)	Sophie Patrício Dora Cabete ccdrc.projects@ccdrc.pt Tel.: +351 239400100
The South African Medical Research Council, (SAMRC)	South Africa	Rizwana Mia Rizwana.Mia@mrc.ac.za Tel: +27 21 938 0984
National Institute of Health Carlos III, (ISCIII)	Spain	María Callejo Arranz mcallejo@isciii.es Tel.: +34918222503
Consejería de Salud y Consumo de la Junta de Andalucía, (CSCJA)	Spain (Andalusia)	Alicia Milano Curto ep.fps@juntadeandalucia.es
Health Department – Generalitat de Catalunya, (DS-CAT)	Spain (Catalonia)	Montserrat Llavayol peris@gencat.cat Tel.: +34 935566103
Government of Navarre, (CFN)	Spain (Navarre)	Javier Rodrigo Javier.rodrigo.aznarez@navarra.es Tel.: +34 848 42 76 69
Sweden´s Innovation Agency, (VINNOVA)	Sweden	Malin Eklund Malin.eklund@Vinnova.se Tel.: +46 730 20 39 53 Casper Ullsten-Wahlund casper.ullsten-wahlund@vinnova.se Tel.: +46 8 473 32 06
The Scientific and Technological Research Council of Turkey, (TUBITAK)	Turkiye	N. Selcan TÜRKER selcan.turker@tubitak.gov.tr Tel.: +90 312 298 1760